Market closedNon-fractional

Cue Biopharma/CUE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Ticker

CUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

53

Cue Biopharma Metrics

BasicAdvanced
$47M
Market cap
-
P/E ratio
-$1.06
EPS
1.99
Beta
-
Dividend rate
$47M
1.99
2.469
2.345
19.385
43.265
-45.95%
-47.26%
-117.50%
6.422
1.54
1.54
-1.157
1,525.00%
-20.69%
22.62%
-10.81%

What the Analysts think about Cue Biopharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Cue Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-723.52% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
-5.56%
Net income
-$12M
-8.21%
Profit margin
-723.52%
-2.81%

Cue Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.24
-$0.29
-$0.25
-
Expected
-$0.31
-$0.34
-$0.28
-$0.28
-$0.29
Surprise
-4.92%
-29.93%
4.32%
-11.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cue Biopharma stock?

Cue Biopharma (CUE) has a market cap of $47M as of July 06, 2024.

What is the P/E ratio for Cue Biopharma stock?

The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of July 06, 2024.

Does Cue Biopharma stock pay dividends?

No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cue Biopharma dividend payment date?

Cue Biopharma (CUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Cue Biopharma?

Cue Biopharma (CUE) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Cue Biopharma stock

Buy or sell Cue Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing